INNOVA-P2
Pharma-Innovation - Patent-2
| Coordinatore | UNIVERSITY OF CENTRAL LANCASHIRE
Organization address
address: - contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 930˙130 € |
| EC contributo | 728˙640 € |
| Programma | FP7-SIS
Specific Programme "Capacities": Science in society |
| Code Call | FP7-SCIENCE-IN-SOCIETY-2007-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-06-01 - 2011-05-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF CENTRAL LANCASHIRE
Organization address
address: - contact info |
UK (PRESTON) | coordinator | 0.00 |
| 2 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 0.00 |
| 3 |
CHINESE ACADEMY OF SCIENCE AND TECHNOLOGY FOR DEVELOPMENT*CASTED
Organization address
address: YU YUAN TAN NAN LU RD 8YU 8 contact info |
CN (BEIJING) | participant | 0.00 |
| 4 |
FORSKNINGSSTIFTELSEN FAFO
Organization address
address: BORGGATA 2B contact info |
NO (OSLO) | participant | 0.00 |
| 5 |
RESEARCH AND INFORMATION SYSTEM FOR DEVELOPING COUNTRIES
Organization address
address: "LODHI ROAD, INDIA HABITAT CENTRE, CORE 4B 4th FLOOR" contact info |
IN (NEW DELHI) | participant | 0.00 |
| 6 |
UNIVERSITY OF MELBOURNE
Organization address
address: PARKVILLEOFFICE OF THE VICE CHANCELLOR contact info |
AU (MELBOURNE) | participant | 0.00 |
| 7 |
UNIVERSITY OF THE PHILIPPINES MANILA
Organization address
address: "TAFT AVENUE, PHILIPPINE GENERAL 8" contact info |
PH (MANILA) | participant | 0.00 |
| 8 |
WAGENINGEN UNIVERSITY
Organization address
address: DROEVENDAALSESTEEG 4 contact info |
NL (WAGENINGEN) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'We seek to develop a plan for amending the current Intellectual Property Rights (IPR) regime for rewarding pharmaceutical innovations. The existing IPR regime is highly problematic. This has become obvious in the wake of a series of public health emergencies, most notably the AIDS crisis, which pits the vital needs of poor patients against the need of pharmaceutical companies to recoup their investments. Amending the current system represents one of the major 21st century challenges, namely delivering reasonably priced health care to patients around the world. This is a challenge that lies at the heart of biomedical ethics striving for sustainable world development. Our effort to take up the challenge focuses on a potential two-tiered patent system. This scheme would create a new patent (Patent-2) that is complementary to existing monopoly patents, leaving innovators free to choose a patent of either kind. Patent-2 holders would not have veto powers over the reproduction of their inventions, thus allowing medicines to become available at competitive market prices without delay. Patent-2 holders would be rewarded, out of public funds, in proportion to the impact of their invention on the global burden of disease. A first sketch of the “Patent-2” scheme has already been developed through a grant from the Australian Research Council. However, the system is now in urgent need of development with input from a range of experts and policy-makers. In order to forge a policy consensus, some of the most influential social philosophers and economists world-wide (Nobel Laureate Joseph Stiglitz, Peter Singer and Thomas Pogge) will be joined by key policy institutes to use their cumulative weight to enhance and promote a proposal that has the clear potential to provide access to essential medicines to poor patients whilst increasing the possibilities for innovation in the pharmaceutical sector.'